ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,749.00
0.35%
S&P ASX All Technology
3,067.50
0.14%
Brent Oil
84.005
0.07%
US Dollar vs AUD
1.51315
0.16%
Bitcoin
62,985.29
-0.10%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Pharming Group NV (PHAR)

  7. Pharming Group NV (PHAR) News

PHAR

Pharming Group NV (PHAR)

Pharming Group NV
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:PHAR
DateTimeSourceHeadlineSymbolCompany
08/05/202420:04Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHARPharming Group NV
09/01/202401:17Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHARPharming Group NV
27/10/202300:25Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHARPharming Group NV
24/08/202316:00PR Newswire (US)Pharming Group to participate in September investor conferencesNASDAQ:PHARPharming Group NV
14/08/202315:00PR Newswire (US)Pharming Group to convene Extraordinary General Meeting of ShareholdersNASDAQ:PHARPharming Group NV
09/08/202315:00PR Newswire (US)Pharming announces first patient enrolled in Phase III clinical trial of leniolisib for the treatment of APDS in JapanNASDAQ:PHARPharming Group NV
09/08/202315:00PR Newswire (US)Pharming announces first patient enrolled in Phase III clinical trial of leniolisib for the treatment of APDS in JapanNASDAQ:PHARPharming Group NV
04/08/202301:09Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHARPharming Group NV
03/08/202315:00PR Newswire (US)Pharming Group reports second quarter and first half 2023 financial resultsNASDAQ:PHARPharming Group NV
18/07/202315:00PR Newswire (US)Pharming to nominate industry leader Dr. Richard Peters as new Chairman of the BoardNASDAQ:PHARPharming Group NV
18/07/202315:00PR Newswire (US)Pharming to nominate industry leader Dr. Richard Peters as new Chairman of the BoardNASDAQ:PHARPharming Group NV
13/07/202316:00PR Newswire (US)Pharming Group to report second quarter and first half 2023 financial results on August 3NASDAQ:PHARPharming Group NV
13/07/202316:00PR Newswire (US)Pharming Group to report second quarter and first half 2023 financial results on August 3NASDAQ:PHARPharming Group NV
01/06/202320:15Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:PHARPharming Group NV
01/06/202315:00PR Newswire (US)Pharming announces sale of priority review voucherNASDAQ:PHARPharming Group NV
01/06/202315:00PR Newswire (US)Pharming announces sale of priority review voucherNASDAQ:PHARPharming Group NV
25/05/202316:00PR Newswire (US)Pharming Group to attend the following Investor Conferences in JuneNASDAQ:PHARPharming Group NV
25/05/202316:00PR Newswire (US)Pharming Group to attend the following Investor Conferences in JuneNASDAQ:PHARPharming Group NV
18/05/202301:28PR Newswire (US)Pharming Group reports on results of the 2023 Annual General Meeting of ShareholdersNASDAQ:PHARPharming Group NV
11/05/202315:00PR Newswire (US)Pharming Group reports financial results for the first quarter of 2023NASDAQ:PHARPharming Group NV
11/05/202315:00PR Newswire (US)Pharming Group reports financial results for the first quarter of 2023NASDAQ:PHARPharming Group NV
26/04/202316:00PR Newswire (US)Pharming to attend the H.C. Wainwright BioConnect Investor Conference 2023NASDAQ:PHARPharming Group NV
19/04/202316:00PR Newswire (US)Pharming to attend the Van Lanschot Kempen Life Sciences Conference 2023NASDAQ:PHARPharming Group NV
19/04/202315:36PR Newswire (US)Notice of First Quarter 2023 ResultsNASDAQ:PHARPharming Group NV
13/04/202321:11PR Newswire (US)Pharming to present at the 22nd Annual Needham Virtual Healthcare Conference 2023NASDAQ:PHARPharming Group NV
11/04/202322:58Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:PHARPharming Group NV
11/04/202315:00PR Newswire (US)Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S.NASDAQ:PHARPharming Group NV
11/04/202315:00PR Newswire (Canada)Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S.NASDAQ:PHARPharming Group NV
11/04/202315:00PR Newswire (US)Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S.NASDAQ:PHARPharming Group NV
05/04/202320:57Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:PHARPharming Group NV
 Showing the most relevant articles for your search:NASDAQ:PHAR

Your Recent History

ASX
NCM
Newcrest Mining
ASX
CBA
Commonwealth Bank Of Aus...
FX
EURAUD
Euro vs AUD
ASX
AMP
AMP
ASX
XTO
S&P ASX 100
ASX
WOW
Woolworths
ASX
ANZ
Australia And New Zealan...
FTSE
UKX
FTSE 100
NYSE
NKE
Nike
ASX
WDC
Westfield
ASX
CSL
CSL
ASX
XMM
S&P ASX 300 Metals and M...
FX
AUDUSD
AUD vs US Dollar
ASX
TLS
Telstra
FX
AUDCAD
AUD vs CAD
ASX
ORG
Origin Energy
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved